Cocrystal Pharma
Cocrystal Pharma is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics targeting influenza viruses, hepatitis C viruses, and noroviruses. Utilizing structure-based technologies and Nobel Prize-winning expertise, the company creates first-in-class antiviral drugs, including CC-31244, an investigational oral broad-spectrum replication inhibitor for hepatitis C.
Top Stages
1 past transactions
RFS Pharma
Acquisition in 2014
RFS Pharma, LLC is a clinical-stage biopharmaceutical company based in Tucker, Georgia, founded by Dr. Raymond F. Schinazi in 2004. The company specializes in the development of innovative drugs aimed at treating hepatitis infections and emerging viral diseases. With a strong focus on research and development, RFS Pharma leverages its expertise in nucleoside chemistry to discover and develop antiviral agents and other human therapeutics. In 2013, RFS Pharma in-licensed anti-hepatitis technology from Emory University to enhance its drug pipeline. The company is also actively pursuing opportunities to in-license promising new drugs, contributing to the growth of the pharmaceutical industry in Georgia.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.